Asthma diagnosis and treatment – 1015. Improvements in lung function in an indian population with IgE mediated asthma receiving omalizumab in a real-world setting

Abstract

Background Omalizumab is a recombinant humanized anti-IgE monoclonal antibody, indicated for add-on therapy for moderateto severe-persistent allergic (IgE-mediated) asthma. Interim results at the 16 weeks time point of this 52 week study have previously been presented. We present a subgroup analysis looking at the efficacy of omalizumab at 16 weeks in relation to the serum IgE levels at baseline.

DOI: 10.1186/1939-4551-6-S1-P15

Cite this paper

@inproceedings{Guleria2013AsthmaDA, title={Asthma diagnosis and treatment – 1015. Improvements in lung function in an indian population with IgE mediated asthma receiving omalizumab in a real-world setting}, author={Randeep Guleria and Deepak Talwar and Ashok Mahashur and Mangala Kotnis}, booktitle={The World Allergy Organization journal}, year={2013} }